# Satellos Bioscience Inc. (MSLE)

Source: https://www.quantisnow.com/company/MSLE
Generated: 2026-11-06T21:36:04.590Z

- Ticker: MSLE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001421642

## Latest MSLE news and filings

- 2026-11-06 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6777896)
- 2026-11-06 12:00 UTC [Earnings Date] [Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback](https://www.quantisnow.com/insight/satellos-changes-primary-efficacy-endpoint-in-basecamp-phase-2-pediatric-6777874)
- 2026-11-05 21:32 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6777016)
- 2026-11-05 21:32 UTC [Earnings Date] [Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study](https://www.quantisnow.com/insight/satellos-to-host-investor-call-to-provide-an-update-on-6777007)
- 2026-10-27 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6758438)
- 2026-10-27 11:00 UTC [Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience](https://www.quantisnow.com/insight/satellos-establishes-scientific-advisory-board-to-explore-the-biology-of-6758395)
- 2026-10-21 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6752848)
- 2026-10-21 11:00 UTC [Conference Announcement] [Satellos to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/satellos-to-participate-in-upcoming-investor-conferences-6752794)
- 2026-10-05 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6735861)
- 2026-10-05 11:00 UTC [Satellos Granted Composition of Matter Patent for Forazapadin](https://www.quantisnow.com/insight/satellos-granted-composition-of-matter-patent-for-forazapadin-6735841)
- 2026-09-30 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6729876)
- 2026-09-30 11:00 UTC [Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy](https://www.quantisnow.com/insight/satellos-announces-completion-of-enrollment-in-basecamp-phase-2-clinical-6729860)
- 2026-09-24 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6724786)
- 2026-09-15 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6715337)
- 2026-09-15 11:00 UTC [Conference Announcement] [Satellos to Present at the 31st Annual Congress of the World Muscle Society](https://www.quantisnow.com/insight/satellos-to-present-at-the-31st-annual-congress-of-the-6715324)
- 2026-09-09 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6709182)
- 2026-09-09 11:00 UTC [Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247](https://www.quantisnow.com/insight/satellos-announces-forazapadin-as-assigned-international-nonproprietary-name-for-lead-6709158)
- 2026-09-01 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6700464)
- 2026-09-01 11:00 UTC [Conference Announcement] [Satellos to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/satellos-to-participate-in-upcoming-investor-conferences-6700436)
- 2026-08-14 20:31 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6683283)
- 2026-08-14 20:17 UTC [SEC Form SUPPL filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-suppl-filed-by-satellos-bioscience-inc-6682946)
- 2026-08-13 21:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6681184)
- 2026-08-13 21:02 UTC [Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress](https://www.quantisnow.com/insight/satellos-reports-second-quarter-2026-financial-results-and-highlights-company-6681152)
- 2026-08-11 20:16 UTC [SEC Form F-X] [SEC Form F-X filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-f-x-filed-by-satellos-bioscience-inc-6675940)
- 2026-08-11 20:02 UTC [SEC Form F-10 filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-f-10-filed-by-satellos-bioscience-inc-6675612)
- 2026-07-08 10:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6630773)
- 2026-07-08 10:30 UTC [Earnings Date] [Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247](https://www.quantisnow.com/insight/satellos-reports-six-month-interim-trailhead-data-showing-reduced-muscle-fat-6630769)
- 2026-06-29 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6618190)
- 2026-06-29 11:00 UTC [Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy](https://www.quantisnow.com/insight/satellos-receives-fda-fast-track-designation-for-sat-3247-for-the-6618175)
- 2026-06-25 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6615049)
- 2026-06-25 11:00 UTC [Satellos to Present Clinical Program Updates at ICNMD 2026](https://www.quantisnow.com/insight/satellos-to-present-clinical-program-updates-at-icnmd-2026-6615032)
- 2026-06-17 21:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6607139)
- 2026-06-17 21:00 UTC [Leadership Update] [Satellos Bioscience Announces Results of Annual Meeting of Shareholders](https://www.quantisnow.com/insight/satellos-bioscience-announces-results-of-annual-meeting-of-shareholders-6607134)
- 2026-05-27 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6573762)
- 2026-05-27 11:00 UTC [Conference Announcement] [Satellos to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/satellos-to-participate-in-upcoming-investor-conferences-6573733)
- 2026-05-20 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6564355)
- 2026-05-15 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-satellos-bioscience-inc-6555553)
- 2026-05-15 11:00 UTC [Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress](https://www.quantisnow.com/insight/satellos-reports-first-quarter-2026-financial-results-and-highlights-company-6555536)
- 2026-05-12 20:23 UTC [SEC Form SCHEDULE 13G filed by Satellos Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-satellos-bioscience-inc-6548363)
- 2026-04-28 11:49 UTC [Analyst Coverage Initiated] [Guggenheim initiated coverage on Satellos Bioscience with a new price target](https://www.quantisnow.com/insight/guggenheim-initiated-coverage-on-satellos-bioscience-with-a-new-price-6517661)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/MSLE
- Earnings history: https://www.quantisnow.com/earnings/MSLE
- Dividend history: https://www.quantisnow.com/dividends/MSLE
- Insider transactions: https://www.quantisnow.com/insiders/MSLE
- Options chain: https://www.quantisnow.com/options/MSLE
- SEC 8-K filings only: https://www.quantisnow.com/company/MSLE/8-k
- RSS and alerts for MSLE: https://www.quantisnow.com/docs/rss-feeds.md